GP | Brummer GC26 | cs | 6 | 29–42/3M–3F | CsA, Apr, Phototherapy | 90 once/45Q4W/45Q4W, 90Q4W/90Q8W | Success 6/6 | None |
| Amarnani52 | CR | 1 | 56/1F | Phototherapy Aci | SD | Clearance | None |
EP | Santos-Juanes28 | CS | 2 | 32 and 41/2F | CsA, MTX, SCS, PUVA, Efa, anti-TNFα | SD | Success 2/2; PASI 90 | None |
| Viguier53 | CS | 3 | | Anti-TNFα | SD | 33% PASI 50 | -1 sudden death; -Widespread skin Staphylococcus |
| Wang29 | CS | 8 | 28–55/7M–1F | CsA , MTX, PUVA, Efa, alefacept, Aci, anti-TNFα | -7 patients: 45Q4W two doses, -1 patient: 45Q4W two doses + W16 + W 32 | 50% PASI 75; 50% PASI 90 | None |
| Pescitelli27 | CS | 22 | NA/14M–8F | CsA, MTX, SCS, UVB Ret, anti-TNFα | SD | 68.2%; PASI 90 | None |
GPP | Storan30 | CR | 1 | 90/1F | CsA, MTX, Ret, Ada | SD | Success 1/1 | None |
| Arakawa32 | CS | 4 | 20–50/4F | CsA, MTX, Ana, Aci , anti-TNFα | SD | Success 4/4 | None |
| Dauden31 | CR | 1 | 47/1M | None | SD | Success 1/1 | None |
| Matsumoto54 | CR | 1 | 70/1F | CsA, etretinate, IFX | Started at 45 then 90 | Fail 1/1 | None |
PPP | Morales-Munera55 | CS | 5 | 30–50/2M–3F | CsA, MTX, PUVA, Aci, Efa, leflunomide, anti-TNFα | SD | Success 5/5 | None |
| Au56 | open-label study | 20 | 18- 85/9M–11F | Systemic therapy, anti-TNFα | SD | Improvement 12/20, Clearance 7/20 | None |
| Bulai Livideanu57 | CS | 2 | 29 and 42/1F and 1M | CsA, MTX, Ret, phototherapy, anti-TNFα | 45 or 90, not regularly | Success 2/2 | None |
| Bissonnette58 | RCT | 15 | NA/14F–1M | | 45Q4W two doses or placebo | No difference compared to placebo | 1 leg cellulitis |
| Husson35 | CS (PPP + ACH) | 30 | NA | NA | NA | Success 21/30 | 2 PPP worsening, 1 Paradoxical psoriasis, 1 Pneumonia |
ACH | | | 4 | | | | Success 4/4 | |
| Adisen59 | CR | 1 | 50/1M | Dap, CsA, MTX, Ret, phototherapy,anti-TNFα | Start 90 then SD 45 | Success 1/1 | None |
| Palacios-Alvarez33 | CR | 1 | 67/1M | MTX, phototherapy, Aci, anti-TNFα | SD 45 | Success 1/1 | None |
| Saunier60 | CR | 1 | 53/1M | Aci , MTX, phototherapy, CsA, anti-TNFα, Ana | SD 45 | Success 1/1 | None |
| Cymerman34 | CR | 1 | 20/1F | CsA | SD 45 | Success 1/1 | None |
| Adas61 | CR | 1 | 61/1M | Eta | 45Q4W two doses then 90Q8W | Success 1/1 | None |
PRP | Ruiz Villaverde62 | CR | 1 | 45/1M | None | SD 45 | Success 1/1 | None |
| Byekova63 | CR | 1 | 75/1M | IFX, Aci | SD 45 | Success 1/1 | None |
| Chowdhary64 | CR | 1 | 52/1F | Aci, UVB, minocycline, SCS, MTX | SD 90 | Success 1/1 | None |
| Di Stefani65 | CR | 1 | 31/1M | CsA, Aci, MTX | SD 45 | Success 1/1 | None |
| Eytan66 | CR | 1 | 57/1M | MTX, Ret, PUVA, Efa, anti-TNFα | 90Q8W | Success 1/1 | None |
| Humme67 | CR | 1 | 50/1M | Aci, PUVA, CsA, IFX | 45–90 | NA | CD30(+) anaplastic large cell lymphoma |
| Lernia68 | CR | 1 | 29/1F | CsA, MTX, anti-TNFα, PUVA, | SD 45 | Fail 1/1 | None |
| Lwin69 | CS | 2 | 20 and 49/1M and 1F | Ret, phototherapy | -1 patient: SD 45; -1 patient: Started at SD 45 then 90 | Success 2/2 | None |
| Paganelli70 | CR | 1 | 78/1F | Ret, phototherapy, MTX, CsA, IFX | SD 45 | Success 1/1 | None |
| Wohlrab71 | CR | 1 | 28/1M | Aci, Bath-PUVA, | SD 45 | Success 1/1 | None |
| Aragón-Miguel72 | CR | 1 | 30/1M | Aci, PUVA | SD 45 | Success 1/1 | None |
| Feldmeyer73 | CR | 1 | 40/M | None | SD 45 | Success 1/1 | None |
| Kalogeropoulos74 | CR | 1 | 60/1M | Aci | SD 45 | NA | Meningococcal and HSV-2 Meningitis |
| Napolitano75 | CS | 5 | 28–62/3M–2F | CsA, SCS, Aci, MTX | SD 45 | Success 4/5, 1partial improvement | None |
| Craiglow76 | CS | 6 | NA | NB-UVB, PUVA, Ret, MTX, CsA, anti-TNFα, | -5 patients: 0,7 mg/kg-1,1 mg/kg Q12W; -1 patient 1,2 mg/kg Q8W | Success 5/6, 1partial improvement | NA |
| Matsuda77 | CR | 1 | 72/1M | SCS, Secu, IFX, etretinate, CsA, MTX, Apr | SD 45 | Success 1/1 | None |
| Ponholzer78 | CS | 5 | NA/3M–2F | NB-UVB, PUVA, Aci | -3 patients: SD 45; -1 patient: SD 90; -1 patient: Started at SD 45 then 90 | Success 5/5 | NA |
HS | Gulliver79 | CS | 3 | 30–32/1M–2F | ATBs, Ret, anti-TNFα, SCS, Efa | SD 45 | - HS-PGA: 2/3; - DLQI: 2/3; - Pain: 2/3 | None |
| Sharon80 | CR | 1 | 55/1M | ISO, ATBs, SCS, MTX, ada, MMF | SD 45 | Improvement 1/1 | None |
| Baerveldt81 | CR | 1 | 39/1F | Diclofenac/misoprostol, colchicine, CsA | SD 45 | Improvement 1/1 | None |
| Santos-Pérez82 | CR | 1 | 50/1F | ISO, anti-TNFα, SCS | SD 45 | Improvement 1/1 | |
| Blok36 | open-label study | 17 | 20–53/4M–13F | ATBs, ISO, anti-TNFα, SCS | SD | - HiSCR: 8/17; - DLQI: 07/17 | urticaria |
| Romani83 | CS | 12 | 19–60/9M–3F | ATBs, CsA, MTX, AZA, anti-TNFα, Ana | IV loading dose adjusted by weight then SC 90 Q8W | - HiSCR: 8/12; - DLQI: 11/12; - Pain: 11/12 | None |
| Scholl84 | CS | 3 | 25–31/2M–1F | ATBs, Ada, dapsone, Secu | IV loading dose adjusted by weight then SC 90 Q8 or 12W | - SAHS: 3/3; - DLQI: 3/3 | None |
| Takeda85 | CR | 1 | 29/1M | IFX, SCS | 360 IV loading dose then SC 90 Q8W | Improvement 1/1 | Non |
| Montero-Vichez86 | CS | 10 | 14–52/6M–4F | ATBs, Ret, CsA, anti-TNFα, SCS, interferon, phototherapy, | SD | -HSPGA: 7/10; - Pain: 8/10 | None |
| Sánchez-Martínez87 | CS | 6 | 31–59/3M–3F | ATBs, Ret, MTX, finasteride, AZA, Ada | IV loading dose adjusted by weight then SC 90 Q8W | HiSCR: 3/6 | None |
| Hollywood88 | CS | 16 | 22–77/4M–12F | ATBs, Ana, metformine, liragultide, Dap, sironolactone, anti-TNFα. | NA | Improvement 8/16 | Recurrent infection |
| Smith89 | CR | 1 | 49/1F | Anti-TNFα. | SD 90 | Primary Improvement | Multifocal myositis |
| Provini90 | CR | 1 | 17/1F | ATBs, sironolactone, SCS, Ada | 90Q8W then 90Q4W | Improvement 1/1 | None |
| Valenzuela-Ubiña91 | CS | 10 | 26–58/4M–6F | ATBs, Ret, MTX, finasteride, AZA, SCS, metformin, Dap, Ana, CsA, Anti-TNFα. | - 9 patients: 90Q8W; -1 patient: SD 45 | -HSPGA: 9/10 | None |
Neutrophilic diseases | |
PG | Goldminz92 | CR | 1 | 47/1M | SCS, Dap, MTX, CsA, AZA, Anti-TNFα. | 90Q4W then 90Q8W | Complete healing | None |
| Cosgarea93 | CR | 1 | 71/1M | SCS, CsA | NA | Complete healing | None |
| Benzaquen94 | CR | 1 | 56/1F | Ada | SD 45 | Complete healing | None |
| Guenova37 | CR | 1 | 37/1F | SCS | Two doses 45Q4W | Complete healing | None |
| Nunes95 | CR | 1 | 45/1M | SCS, IFX, AZA, CsA | 520 IV loading dose then SC 90 Q8W | Complete healing | None |
| Piqueras-García39 | CR | 1 | 33/1F | SCS, 6-Mercaptopurine, CsA, Anti-TNFα, vedolizumab, tacrolimus | 90 week 0, 4, 10 then Q8W | Complete healing | None |
| Petty40 | CR | 1 | 50/1F | SCS, CsA, IFX | 90 week 0, 4 then Q8W | Complete healing | None |
| Low96 | CS | 3 | 36 –57/3F | SCS, MMF, Dap, IVIG | -1 patient: 90 week 0, 4 then Q6W then 45 Q3W; -2 patient: 90 week 0, 4 then Q8W then 45 Q4W | Complete healing 3/3 | None |
| Greb97 | CR | 1 | 50/1M | SCS, CsA, Anti-TNFα, Dap | 90 Q8W then 90 Q6W then 135 Q6W | Significant improvement | None |
| Fahmy98 | CR | 1 | 34/1F | Tacrolimus, AZA | 90 week 0, 2 then Q8W | Complete healing | None |
| López González99 | CR | 1 | 29/1F | ATB, SCS, Ada | 260 IV loading dose then SC 90 Q8W | Complete healing | None |
| Vallerand100 | CR | 1 | 47/1M | SCS, IVIG, MMP | 520 IV loading dose then SC 90 Q8W | Significant improvement | None |
| Nieto101 | CR | 1 | 62/1M | Ada, Azacytidine, CsA, IFX, IVIG, Thalidomide, SCS | 90 Q8W | Complete healing | None |
| Westerdahl102 | CS | 8 | 24–88/4M–4F | SCS, Anti-TNFα, colchicine, Ixe, ATB, | -3 patients: 90 Q8W; -1 patient: 90 Q12W; -2patients: 45 Q12W; -1 patient: 45 Q8W; -1 patient: 180 Q8W | Complete healing 7/8, improvement 1/8 | None |
| de Risi-Pugliese38 | CS | 4 | 30–44/1F | AZA, IFX, MTX, Ada, AZA, aminosalicylates, Mercaptopurine | -2 patients: 90 Q8W; -1 patient: 90 Q2W then Q8W; -1 patient: 90 Q4W then Q8W | Complete healing ¾; Significant improvement 1/4 | None |
APF | | | 2 | 32 and 41/2F | SCS, Dap, ISO, CsA, colchicine, Ana, ATB, Ada | -1 patient: 90 Q8W; -1 patient: 90 week 0, 2 then Q8W | Significant improvement 2/2 | None |
SS | | | 1 | 28/1M | Colchicine, MTX, SCS, Ada, Dap | 90 Q8W | Fail 1/1 | None |
BD | Baerveldt81 | CR | 1 | 39/1F | diclofenac/misoprostol, colchicine, CsA | SD 45 | Remission | None |
| Lopalco103 | CR | 1 | 36/1F | SCS, colchicine, MTX, CsA, AZA, Anti-TNFα, Ana | SD 45 | Remission | None |
| Mirouse41 | Prospect-ive study | 14 | 34–41/10M–4F | Colchicine, AZA, SCS, MMF, tocilizumab, tacrolimus | -11 patients: SD 90; -3 patients: SD 45 | -Complete response: 9/14; -Partial response: 3/14; -Fail: 2/14 | None |
| Mirouse104 | open-label study | 30 | 33–45/16M–14F | Colchicine, SCS, thalidomide, hydroxyl-chloroquine, MTX, cyclophosphamide, AZA, MMF, everolimus. | SD 90 | -Complete response: 18/30; -Partial response: 9/30; -Fail: 3/30 | None |
| London105 | open-label study | 15 | NA/9M–6F | Colchicine, SCS | SD 90 | -Complete response: 9/15; -Partial response: 2/15; -Fail: 4/15 | None |
AD | Puya106 | CR | 1 | 21/1F | SCS, UVB, CsA, Efa | SD 45 | Complete response | None |
| Agusti-Mejias107 | CR | 1 | 16/1F | SCS, phototherapy, AZA, CsA | SD 45 | Complete response: SCORAD 0 | None |
| Shroff108 | CR | 1 | 70/1F | UVB, CsA, MMF | 45 week 0, 3, 11 and 19 | Complete response: SCORAD 0 | None |
| Fernández-Antón Martínez42 | CS | 4 | 23–29/4M | SCS, phototherapy, AZA, CsA, MTX, MMF | SD 45 | Significant improvements | None |
| Lis-Święty109 | CR | 1 | 21/1M | None | SD 45 | Exacerbation | None |
| Ishiuji110 | CS | 2 | 59 and 39/1M and 1F | None | SD 45 | Exacerbation | None |
| Samorano111 | CS | 2 | 47 and 20/1M and 1F | phototherapy, SCS, CsA, MTX, MMF, Eta | -1 patient: SD 45; -1 patient: 45 week 0, 6, 12 | Fail 2/2 | None |
| Nic Dhonncha112 | CS | 10 | 20–50/8M–2F | phototherapy, AZA, CsA, MMF, Eta, Efa | SD 45 or 90 | Significant improvements: 4/10; Fail: 6/10 | None |
| Saeki113 | RCT phase 2 | 52 vs 27 placebo | 20–57/36M–16F | phototherapy, SCS, CsA | SD 45 or 90 | No significant improvement | None |
| Wlodek114 | CR | 1 | 13/1F | SCS, AZA, CsA, MTX, MMF | SD 45 | Partial improvement | None |
| Khattri115 | RCT phase 2 | 16 vs 15 placebo | NA/10M–16F | NA | SD 45 or 90 | No significant improvement | None |
| Weiss116 | CS | 3 | 27–55/2M–1F | SCS, phototherapy, CsA, MMF | 45 week 0, 4, 12 then Q8W | Improvement 3/3 | None |
AA | Guttman-Yassky43 | CS | 3 | NA/2M–1F | NA | SD 90 (3 doses) | Improvement 3/3 | None |
| Aleisa44 | CS | 3 | 9–16/3F | SCS, | 1 patient: 90 week 0, 12, 24; 2 patients: one dose 90 | Significant hair regrowth 3/3 | None |
| Ortolan117 | CS | 4 | 8–44/2M–2F | SCS, CsA, MTX, ruxolitinib, tofacitinib | 1 patient: 45 week 0, 60 week 90 week 12, 20; 1 patient: 90 Q8W; 2patients: 90 week 0, 4, 12 | Fail 4/4 | None |
| Elkady34 | CR | 1 | 39/1F | Vitamines B complex | 90 week 0, 4 then Q8W | Hair regrowth | None |
Vitiligo | | | | | None | | Repigmentation | |
SAPHO | Wendling46 | CS | 3 | 32–61/3F | Phototherapy, MTX, CsA, Anti-TNFα | SD 90 | Remission 1/3 | Paradoxical psoriasis |
| Firinu117 | CR | 1 | NA/1F | anti-TNF-α, Ana | SD 90 | Significant improvement | None |
LP | Solimani47 | CS | 1 | 72/1F | CsA, SCS, Aci,AZA | SD 45 | Significant improvement | None |
| Webster48 | CR | 1 | 70/1F | Hydroxychloroquine | SD 45 | Fail | None |
LP pemphigoides | Knisley118 | CR | 1 | 71/1F | Cycline, nicotinamide, SCS, Dap, AZA, MMF Hydroxychloroquine | SD 45 | Significant improvement | None |
BP | Loget49 | CR | 1 | 88/1F | None | SD 45 | Remission | None |
antilaminin-γ1 pemphigoid | Majima119 | CR | 1 | 69/1M | SCS, Ada | NA | Remission | None |
Cutaneous lupus | De Souza120 | CR | 1 | 58/1F | NA | SD 45 | Remission | None |
| Varada122 | CS | 1 | 68/1F | NA | NA | Remission | None |
| Dahl51 | CR | 1 | 79/1F | SCS, hydroxychloroquine, AZA, thalidomide, MTX, IV IG | 45 week 0, 4, 16, 34 | Improvement | None |
| Winchester50 | CR | 1 | 41/1M | MTX, hydroxychloroquine, CsA | SD 45 then 90 | Significant improvement | None |
| Mazgaj122 | CR | 1 | 65/1F | Chloroquine, Aci, MTX, CsA, thalidomide, lenalidomide, alitretinoin. | SD 45 then 90 Q8W | Remission | None |